EYLEA enables proactive therapy approved for multiple retinal diseases.
EYLEA is the only anti-angiogenic therapy that inhibits vascular endothelial growth factor A (VEGF-A) and Placental Growth Factor (PlGF).
EYLEA's license may allow for a proactive, treat-and-extend dosing approach that is approved for the treatment of:
Click on each of the links below to view related animations and videos.
STORE currently on DEMO only; no orders fulfilled.